A trial led by the University of Oxford results in another solution to fight COVID-19. The recent study was made possible through the help of 8,000 participants who were each hospitalized with the coronavirus.
Baricitinib: Potential Drug Against COVID-19 Death Risk
Each of the patients included in the trials received the standard treatments pushed by the National Health Service (NHS). Half of the total participants were given an oral drug known as baricitinib.
The experts found that 33 fewer deaths occurred in the group who took the drugs than the separate group that received the standard treatments. The team behind the study concluded that, by including the baricitinib to COVID-19 solutions, patients would have a lesser risk by 13 percent.
The authors added that the effect of the baricitinib could exceed the rates observed in the study and could benefit people up to 20 percent.
University of Oxford's epidemiology expert and lead of the recovery trials, Martin Landray, explained that the results they gathered serve as a huge advancement towards finding the best medicinal prescription against the coronavirus.
Baricitinib is already at work since November 2020 and has been given as an additional drug to COVID-19 patients in the United States.
Baricitinib was approved five years ago to treat the common rheumatoid arthritis, a condition where the immune system is attacking the joints. The disease results in the inflammation of the affected areas. The medicine's role is to reduce the impact of arthritis, such as swelling and pain.
According to the new research, the capability of the baricitinib drug can also help coronavirus patients heal damaged organs to prevent the risk of death.
Baricitinib is exclusively available through a prescription from a health professional. In the United Kingdom, the drug is known under the brand Olumiant. This same medicine was involved in the latest trials and gave a promising result and other baricitinib samples.
ALSO READ: Pennsylvania Cat Catches COVID-19 Delta Variant But It May Not Mutate Much in Other Felines
Arthritis Drugs vs. Coronavirus-Related Deaths
Along with baricitinib, a separate drug called dexamethasone was also found with potential against COVID-19. According to the experts, the medicine decreased the risk of death by a fifth in coronavirus patients.
Many have utilized Dexamethasone and has been present in the pharmaceutical industry for decades now. The impact of the drug was observed in June 2020. After eight months, the experts also discovered a good outcome in patients given an immunosuppressive drug called tocilizumab.
The participants involved in the study averaged 58 years of age. Each of the individuals was observed between February and December 2020.
Two-thirds of the participants relied on oxygen supply, and a quarter was given other respiratory assistance types.
Corticosteroid like dexamethasone is already relayed to the majority of the participants throughout the study.
Results showed that the baricitinib group had 513 deaths within 28 days, or about 12 percent of the overall participants, while the 'standard' group had 546 deaths or approximately 14 percent of the total.
Baricitinib performed consistent results regardless of other treatments a patient receives, including the COVID-19 vaccines. The study's pre-print was published in BMJ, titled "Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial."
RELATED ARTICLE: Coronavirus Pandemic Origin Still Points to Animals Sold in Wuhan Wet Market, Latest Study States
Check out more news and information on COVID-19 in Science Times.
